Researchers find drug for Alzheimer’s disease without inflammatory side effects
The US Food and Drug Administration has approved Aduhelm, a monoclonal antibody that targets amyloid beta (A), as the first therapy for Alzheimer’s disease (AD). However, its effect on cognitive enhancement is still being debated. Furthermore, approxi...
5 August, 2022
Read more